SCHEDULE: Bank of America Discloses 21.5% Stake in ENvue Medical

Bank of America Corporation has disclosed a 21.5% beneficial ownership stake in ENvue Medical, Inc., holding 234,235 common shares, with a significant warning of potential future dilution.

Summary

• Bank of America Corporation /DE/ has reported beneficial ownership of 234,235 shares of ENvue Medical, Inc. common stock.
• This represents 21.5% of the company's outstanding common stock, based on 1,088,192 shares as of December 5, 2025.
• The ownership is held through its wholly-owned subsidiaries, BofA Securities, Inc. and Bank of America N.A.
• A prospectus for the resale of up to 7,962,279 shares by selling stockholders has been noted.
• A significant risk of substantial dilution to existing stockholders is highlighted due to the potential issuance of additional shares, which could materially increase the number of outstanding common shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution. While Bank of America's significant stake could be seen as a positive, the explicit warning of substantial dilution from a potential large share issuance by selling stockholders introduces a strong negative sentiment for existing shareholders.

Positives

• A major financial institution, Bank of America, holds a significant stake (21.5%) in ENvue Medical, which could be interpreted as a signal of institutional interest or confidence in the company's long-term prospects.

Negatives

• The potential issuance of up to 7,962,279 additional shares of common stock could lead to substantial dilution for existing stockholders.
• This potential dilution represents a significant increase over the current 1,088,192 outstanding shares.

Risks

• Substantial dilution to existing stockholders due to the potential issuance of additional common shares.
• A material increase in the number of outstanding common shares from the resale of up to 7,962,279 shares by selling stockholders.

Future Outlook

The filing indicates a future event involving the potential resale of up to 7,962,279 shares of common stock by selling stockholders. This could lead to a material increase in outstanding shares and substantial dilution for existing stockholders, though it is noted as 'not yet finalized.'

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive institutional investment, where the holder does not intend to influence control of the company. While a significant stake from a major bank like Bank of America can signal institutional interest, the accompanying disclosure of potential massive dilution from a prospectus for resale of shares by selling stockholders introduces a substantial cautionary note. This suggests that while there's institutional presence, the market might soon face a significant increase in the float, potentially impacting share price dynamics.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Existing shareholders face a significant risk of substantial dilution if the 7,962,279 shares mentioned in the prospectus are issued, potentially decreasing the value of their current holdings.
• Investors: Potential investors need to consider the impact of future dilution on the company's share price and market capitalization.

Next Steps

• Monitoring for the finalization and execution of the prospectus for the resale of up to 7,962,279 shares by selling stockholders.

Key Dates

Recommendation

The explicit warning of "substantial dilution to existing stockholders" from the potential issuance of up to 7,962,279 shares, which is nearly 7.3 times the current outstanding shares, presents a severe negative outlook for the stock. This level of dilution is highly likely to depress share price significantly, making a "sell" recommendation prudent for existing holders to mitigate potential losses, and advising against new positions until the dilution event is clarified or resolved.

Keywords

ENvue Medical, Bank of America, Schedule 13G, beneficial ownership, common stock, dilution, SEC filing, institutional investment, equity, prospectus, share resale